Table 2. Mortality risks according to four categories of cystatin-C based estimated glomerular filtration rate (eGFR).
| Cystatin C-based eGFR, ml/min/1.73m2 | ≥90 | 60–89 | 30–59 | <30 | P for Trend |
|---|---|---|---|---|---|
| All-cause mortality | |||||
| No patients | 1517 | 2162 | 809 | 73 | |
| Person-years (py) | 10191.26 | 13804.35 | 4487.60 | 357.20 | |
| No deaths | 154 | 367 | 316 | 36 | |
| AR per 100 py (95%-CI) | 1.51 (1.29 to 1.77) | 2.66 (2.40 to 2.94) | 7.04 (6.33 to 7.83) | 10.08 (7.37 to 13.64) | |
| Crude | 1 | 1.79 (1.48 to 2.16) | 4.93 (4.07 to 5.98) | 7.30 (5.08 to 10.50) | <0.001 |
| Age & sex adj. | 1 | 1.46 (1.20 to 1.77) | 3.31 (2.67 to 4.11) | 4.80 (3.29 to 7.00) | <0.001 |
| Model 1 | 1 | 1.37 (1.12 to 1.67) | 2.85 (2.28 to 3.55) | 4.38 (2.99 to 6.42) | <0.001 |
| Model 2 | 1 | 1.33 (1.09 to 1.63) | 2.74 (2.20 to 3.42) | 4.15 (2.83 to 6.09) | <0.001 |
| Cardiovascular mortality | |||||
| No deaths | 57 | 150 | 145 | 18 | |
| Crude | 1 | 1.97 (1.45 to 2.67) | 6.10 (4.49 to 8.29) | 9.78 (6.75 to 16.62) | <0.001 |
| Age & sex adj. | 1 | 1.62 (1.18 to 2.22) | 4.15 (2.95 to 5.83) | 6.50 (3.74 to 11.30) | <0.001 |
| Model 1 | 1 | 1.55 (1.13 to 2.14) | 3.61 (2.55 to 5.10) | 6.04 (3.44 to 10.58) | <0.001 |
| Model 2 | 1 | 1.52 (1.11 to 2.10) | 3.49 (2.47 to 4.95) | 5.76 (3.28 to 10.11) | <0.001 |
| Cancer mortality | |||||
| No deaths | 71 | 142 | 91 | 5 | |
| Crude | 1 | 1.50 (1.13 to 2.00) | 3.07 (2.25 to 4.19) | 2.20 (0.89 to 5.45) | <0.001 |
| Age & sex adj. | 1 | 1.30 (0.97 to 1.76) | 2.31 (1.63 to 3.28) | * | |
| Model 1 | 1 | 1.23 (0.91 to 1.66) | 2.11 (1.48 to 3.01) | * | |
| Model 2 | 1 | 1.20 (0.89 to 1.62) | 2.02 (1.41 to 2.88) | * | |
| Non-cardiovascular/non-cancer mortality | |||||
| No deaths | 26 | 75 | 80 | 13 | |
| Crude | 1 | 2.17 (1.39 to 3.39) | 7.49 (4.81 to 11.66) | 15.90 (8.16 to 30.99) | <0.001 |
| Age & sex adj. | 1 | 1.56 (0.98 to 2.48) | 4.02 (2.46 to 6.58) | 8.41 (4.18 to 16.94) | <0.001 |
| Model 1 | 1 | 1.38 (0.87 to 2.20) | 3.11 (1.89 to 5.12) | 6.72 (3.29 to 13.70) | <0.001 |
| Model 2 | 1 | 1.35 (0.85 to 2.15) | 3.00 (1.82 to 4.95) | 6.38 (3.12 to 13.04) | <0.001 |
AR absolute risk, CI confidence interval, No number, py person years, Model 1: adjusted for the intervention with n-3 fatty acids, age, sex, diabetes, current smoking, ratio serum total cholesterol/HDL, statin-use, anti-hypertensive medication, systolic blood pressure, and diastolic blood pressure. Model 2: in addition to Model 1 additional adjustment for C-reactive protein. eGFR ≥90 ml/min/1.73m2 was taken as the reference category.
*Due to the low number of events in the lowest category of eGFR further adjustment could not be performed.